167 related articles for article (PubMed ID: 36500446)
21. Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo.
Jafri SH; Glass J; Shi R; Zhang S; Prince M; Kleiner-Hancock H
J Exp Clin Cancer Res; 2010 Jul; 29(1):87. PubMed ID: 20594324
[TBL] [Abstract][Full Text] [Related]
22. miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2.
Qiu T; Zhou L; Wang T; Xu J; Wang J; Chen W; Zhou X; Huang Z; Zhu W; Shu Y; Liu P
Int J Mol Med; 2013 Sep; 32(3):593-8. PubMed ID: 23856992
[TBL] [Abstract][Full Text] [Related]
23. Enhancement effect of adenovirus-mediated antisense c-myc and caffeine on the cytotoxicity of cisplatin in osteosarcoma cell lines.
Xie XK; Yang DS; Ye ZM; Tao HM
Chemotherapy; 2009; 55(6):433-40. PubMed ID: 19996588
[TBL] [Abstract][Full Text] [Related]
24. Expression of apoptosis-related proteins and morphological changes in a rat tumor model of human small cell lung cancer prior to and after treatment with radiotherapy, carboplatin, or combined treatment.
Fokkema E; De Vries EG; Groen HJ; Meijer C; Timens W
Virchows Arch; 2003 Apr; 442(4):349-55. PubMed ID: 12715170
[TBL] [Abstract][Full Text] [Related]
25. ZM447439, the Aurora kinase B inhibitor, suppresses the growth of cervical cancer SiHa cells and enhances the chemosensitivity to cisplatin.
Zhang L; Zhang S
J Obstet Gynaecol Res; 2011 Jun; 37(6):591-600. PubMed ID: 21159048
[TBL] [Abstract][Full Text] [Related]
26. PD-0332991 combined with cisplatin inhibits nonsmall cell lung cancer and reversal of cisplatin resistance.
Liu M; Cui L; Li X; Xia C; Li Y; Wang R; Ren F; Liu H; Chen J
Thorac Cancer; 2021 Mar; 12(6):924-931. PubMed ID: 33534964
[TBL] [Abstract][Full Text] [Related]
27. MK2206 potentiates cisplatin-induced cytotoxicity and apoptosis through an interaction of inactivated Akt signaling pathway.
Sun D; Sawada A; Nakashima M; Kobayashi T; Ogawa O; Matsui Y
Urol Oncol; 2015 Mar; 33(3):111.e17-26. PubMed ID: 25499922
[TBL] [Abstract][Full Text] [Related]
28. Src homology phosphotyrosyl phosphatase 2 mediates cisplatin-related drug resistance by inhibiting apoptosis and activating the Ras/PI3K/Akt1/survivin pathway in lung cancer cells.
Tang C; Luo H; Luo D; Yang H; Zhou X
Oncol Rep; 2018 Feb; 39(2):611-618. PubMed ID: 29207183
[TBL] [Abstract][Full Text] [Related]
29. Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line.
Sawada S; Mese H; Sasaki A; Yoshioka N; Matsumura T
Cancer Chemother Pharmacol; 2003 Jun; 51(6):505-11. PubMed ID: 12709826
[TBL] [Abstract][Full Text] [Related]
30. Cisplatin Synergistically Enhances Antitumor Potency of Conditionally Replicating Adenovirus via p53 Dependent or Independent Pathways in Human Lung Carcinoma.
Ali S; Tahir M; Khan AA; Chen XC; Ling M; Huang Y
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30841620
[TBL] [Abstract][Full Text] [Related]
31. Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer cells to cisplatin through inhibiting the Notch1 signaling pathway.
Bai L; Wang A; Zhang Y; Xu X; Zhang X
Exp Cell Res; 2018 May; 366(2):161-171. PubMed ID: 29548748
[TBL] [Abstract][Full Text] [Related]
32. Apoptosis of bladder cancer by sodium butyrate and cisplatin.
Maruyama T; Yamamoto S; Qiu J; Ueda Y; Suzuki T; Nojima M; Shima H
J Infect Chemother; 2012 Jun; 18(3):288-95. PubMed ID: 22041988
[TBL] [Abstract][Full Text] [Related]
33. miR-135a/b modulate cisplatin resistance of human lung cancer cell line by targeting MCL1.
Zhou L; Qiu T; Xu J; Wang T; Wang J; Zhou X; Huang Z; Zhu W; Shu Y; Liu P
Pathol Oncol Res; 2013 Oct; 19(4):677-83. PubMed ID: 23640248
[TBL] [Abstract][Full Text] [Related]
34. Trichostatin A sensitizes cisplatin-resistant A549 cells to apoptosis by up-regulating death-associated protein kinase.
Wu J; Hu CP; Gu QH; Li YP; Song M
Acta Pharmacol Sin; 2010 Jan; 31(1):93-101. PubMed ID: 20048748
[TBL] [Abstract][Full Text] [Related]
35. miR-181a and miR-630 regulate cisplatin-induced cancer cell death.
Galluzzi L; Morselli E; Vitale I; Kepp O; Senovilla L; Criollo A; Servant N; Paccard C; Hupé P; Robert T; Ripoche H; Lazar V; Harel-Bellan A; Dessen P; Barillot E; Kroemer G
Cancer Res; 2010 Mar; 70(5):1793-803. PubMed ID: 20145152
[TBL] [Abstract][Full Text] [Related]
36. YM155 sensitizes ovarian cancer cells to cisplatin inducing apoptosis and tumor regression.
Mir R; Stanzani E; Martinez-Soler F; Villanueva A; Vidal A; Condom E; Ponce J; Gil J; Tortosa A; Giménez-Bonafé P
Gynecol Oncol; 2014 Jan; 132(1):211-20. PubMed ID: 24262875
[TBL] [Abstract][Full Text] [Related]
37. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
[TBL] [Abstract][Full Text] [Related]
38. Effects of naringin on reversing cisplatin resistance and the Wnt/
Zhu H; Zou X; Lin S; Hu X; Gao J
J Int Med Res; 2020 Oct; 48(10):300060519887869. PubMed ID: 33086930
[TBL] [Abstract][Full Text] [Related]
39. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
[TBL] [Abstract][Full Text] [Related]
40. Poor expression of microRNA-135b results in the inhibition of cisplatin resistance and proliferation and induces the apoptosis of gastric cancer cells through MST1-mediated MAPK signaling pathway.
Zhou J; Chen Q
FASEB J; 2019 Mar; 33(3):3420-3436. PubMed ID: 30576232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
